The estimated Net Worth of Natalie Bogdanos is at least $683 Tausend dollars as of 25 July 2017. Ms. Bogdanos owns over 800 units of ContraFect Corp stock worth over $185 and over the last 10 years she sold CFRX stock worth over $0. In addition, she makes $683,199 as General Counsel und Corporate Secretary at ContraFect Corp.
Natalie has made over 1 trades of the ContraFect Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently she bought 800 units of CFRX stock worth $992 on 25 July 2017.
The largest trade she's ever made was buying 800 units of ContraFect Corp stock on 25 July 2017 worth over $992. On average, Natalie trades about 80 units every 0 days since 2015. As of 25 July 2017 she still owns at least 800 units of ContraFect Corp stock.
You can see the complete history of Ms. Bogdanos stock trades at the bottom of the page.
Natalie Bogdanos J.D. serves as General Counsel, Corporate Secretary of the Company. She has served as our General Counsel and Corporate Secretary since August 2014, and served as a member of the Interim Office of the Chief Executive Officer from March 2017 to June 2017. Ms. Bogdanos has also served as our Data Protection Officer since July, 2018. She has over 20 years of experience in the legal field, almost 14 of which were serving as the chief legal officer of a publicly traded biotechnology company. Prior to joining ContraFect in 2014, Ms. Bogdanos served as a full time legal consultant for Ferring Pharmaceuticals, Inc. from January 2014 to August 2014. Prior to that, Ms. Bogdanos served as Associate General Counsel at Memorial Sloan-Kettering Cancer Center (“MSKCC”), a cancer treatment and research institution, where she held a joint appointment with the Office of the General Counsel and the Office of Technology Development (“OTD”) from 2012 to 2013. At MSKCC, she provided legal counsel and guidance to various departments throughout the institution while having sole responsibility for the legal oversight of the OTD. Prior to MSKCC, she was General Counsel at Enzo Biochem, Inc. (“Enzo”), a publicly traded international biotechnology and life science company, from 2003 to 2012. At Enzo, she was responsible for leading the legal department, ensuring SEC and regulatory compliance, overseeing litigation and managing Enzo’s portfolio of 500+ patents and patent applications and negotiating complex business development agreements as well as other contracts. Ms. Bogdanos received her J.D. from New York Law School and her Bachelor of Arts in Biology, with honors, from Queens College of the City University of New York.
As the General Counsel und Corporate Secretary of ContraFect Corp, the total compensation of Natalie Bogdanos at ContraFect Corp is $683,199. There are 5 executives at ContraFect Corp getting paid more, with Roger Pomerantz having the highest compensation of $1,875,610.
Natalie Bogdanos is 51, she's been the General Counsel und Corporate Secretary of ContraFect Corp since 2014. There are 14 older and 2 younger executives at ContraFect Corp. The oldest executive at ContraFect Corp is Sol Barer, 72, who is the Lead Independent Director.
Natalie's mailing address filed with the SEC is C/O CONTRAFECT CORPORATION, 28 WELLS AVENUE, 3RD FLOOR, YONKERS, NY, 10701.
Over the last 10 years, insiders at ContraFect Corp have traded over $2,523,392 worth of ContraFect Corp stock and bought 525,578 units worth $426,359 . The most active insiders traders include Sol J Barer, Roger Pomerantz und Industrial Co., Ltd Fosun. On average, ContraFect Corp executives and independent directors trade stock every 70 days with the average trade being worth of $16,159. The most recent stock trade was executed by Michael Messinger on 13 December 2019, trading 5,000 units of CFRX stock currently worth $1,850.
we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba
ContraFect Corp executives and other stock owners filed with the SEC include: